CymaBay Therapeutics, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CBAY
  • 1d0.03%
  • 1w0.00%
  • 1m0.78%
  • 1y261.69%
ATH
  • ATH Price$32.48
  • ATH Date2024-03-19
  • % since ATH0.00%
  • % to ATH0%
ATL
  • ATL Price$0.93
  • ATL Date2016-02-11
  • % from ATL3,399.25%
  • Last Low Price$32.47
  • Last Low Date2024-03-20
  • % From Last Low0.03%
IPO
  • IPO Price$9.00
  • % Current ROI USD360.89%
  • ATH Price$32.48
  • % ROI ATH 349,924.59%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CBAY"]

Key Data [addtoany]

Current price $32.48
Sector Healthcare
Industry Biotechnology
Today's High/Low $32.48/$32.48
Volume 0.00
Previous Close $32.47
52 Week High/Low $32.5/$7.2609
Market Cap 3,728,216,832.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-1.05
Annualized Dividend $0
$32.48
[addtoany]

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition.
Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc.
to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity